Taken from Daily Recird dated 28 July 2018
Patients, including Theresa May who relies on insulin , could be "seriously disadvantaged" in the event of a no-deal Brexit , the chairman of the UK's medicines regulator has warned.
Sir Michael Rawlins, of the Medicines and Healthcare Products Regulatory Agency (MHRA), said supplies of insulin and other medication which is not manufactured in the UK, may be disrupted in such a scenario.
Officials need to make sure drugs do not run out if a deal with the European Union is not reached, Sir Michael told the Pharmaceutical Journal.
The Prime Minister, who has Type 1 diabetes, has previously said she regularly injects with insulin to manage the condition.
READ MORE
Brexit Secretary Dominic Raab targeted in 'Scotland is region of England' fake tweet scam
The comments come after new Health and Social Care Secretary Matt Hancock revealed officials are considering working with the industry to stockpile drugs, medical devices and supplies in the event of a no-deal.
Speaking in an "personal capacity", Sir Michael told the Pharmaceutical Journal: "There are problems, and the Department for Exiting the EU and the Department of Health and Social Care need to work out how it's going to work.
"Here's just one example why: We make no insulin in the UK. We import every drop of it.
"You can't transport insulin around ordinarily because it must be temperature-controlled."
Many diabetic people rely on insulin, Sir Michael said, "not least the Prime Minister".
He added: "Disruption to the supply chain is one of the ways that patients could be seriously disadvantaged.